4 Townsend West
275 articles with iCAD, Inc.
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access EventNew ProFound AI risk software, offering a 2-year projected risk score to be featured
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.
Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution
iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography , the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI)
iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution
Leading Clinical Experts Discuss Advancing Personalized Breast Cancer Screening and Detection with Newly Launched ProFound AI Risk Added Market Growth Opportunit y Presented by Pioneering AI Breast Cancer Risk Offering Webinar Taking Place on Monday, December 7 @ 11am ET
iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company is showcasing its leading Breast Health Solutions , including the expanded ProFound AI ® platform powered by Panorama, at the 106 th Scientific Assembly and virtual Annual Meeting of the Radiological Society of North America (RSNA), November 29 – December 5. The Company’s full sui
Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft ® Axxent ® Electronic Brachytherapy (eBx ® ) System ® at the American Society for Radiation Oncology ( ASTRO ) Virtual Annual Meeting, October 24-28, 2020. Researchers will present new data supporting the Xoft System for the treatment of early-s
New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent GlioblastomaNew, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery
iCAD, Inc. announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy System® for the treatment of recurrent glioblastoma, will be presented at the European Association of Neurosurgical Societies Virtual Congress, October 19- 21, 2020.
iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced
iCAD, Inc. is providing additional comments following the Centers for Medicare & Medicaid Services’ publication of a new Innovation Center model designed, according to CMS, to improve the quality of care for cancer patients receiving radiotherapy and reduce Medicare expenditures through bundled payments.
iCAD Hosts Free Virtual Roundtable Event Focusing on Making Informed Decisions for Adopting New AI Solutions and Practical Applications in Healthcare
Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Guggenheim MedTech Disruptors Summit, taking place virtually on August 10-11, 2020.
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2020.
iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft. “We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, and revenue growth,” said Stacey Stevens, President of iC
iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the company has been added to the Russell 2000® Index and the Russell 3000® Index at the conclusion of this year’s reconstitution of the Russell stock indexes, effective upon the opening of the U.S. stock markets today, Monday, June 29, 2020. “We are pleased to be included in the Russell 2000® Inde
Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure
iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Promising clinical research supports Xoft brain IORT as a viable treatment option forglioblastoma multiforme that may extend patients’ lives
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
iCAD, Inc. announced that it will release financial results for the first quarter ended March 31, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Monday, May 11.
iCAD, Inc. announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering.
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it has entered into a credit facility with Bridge Bank, a division of Western Alliance Bank, effective March 30, 2020.